Clinical trials: Antiviral Treatment
HEPATITIS B CHRONIC
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
- Trial name
- ELIMINATE-B (NCT06680232)
- Testing
- PBGENE-HBV
- Where
- 7 sites in United States, France and 4 more
- Volunteers
- 45 people
- Sponsor
- Precision BioSciences, Inc.
Hepatitis B
Maternal Antiviral Treatment and Infants Immunoprophylaxis in the Prevention of Mother-to-child Transmission
The effective control of nucleos(t)ide analogues for patients infected with hepatitis B has significantly curbed the horizontal transmission of hepatitis B.
- Trial name
- NCT03977987
- Testing
- nucleos(t)ide analogue
- Where
- China
- Volunteers
- 233 people
- Sponsor
- Huashan Hospital
Herpes Zoster, Postherpetic Neuralgia
Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)
A multi-center, randomized, 4-arm, placebo-controlled, double-blind efficacy study of ARYS-01 (sorivudine) cream 3%.
- Trial name
- NCT00652184
- Testing
- valaciclovir
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- aRigen Pharmaceuticals, Inc.
Hepatitis C, Public Health
HCV RAS Testing in Public Health Programs
Successful treatment of hepatitis C has been reported to be associated with 62-84% reduction in all-cause mortality (deaths), 68-79% reduction in risk of HCC and 90% reduction in risk of liver transplantation.
- Conditions
- Hepatitis C, Public Health, Direct Acting Antiviral Agents, Resistance Associated Substitutions
- Trial name
- RAS-HCV (NCT04242433)
- Testing
- Direct Acting Antivirals
- Where
- 2 sites in India
- Volunteers
- 200 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Chronic Hepatitis C
The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs
Hepatitis C virus (HCV) infection is easy to chronic and can progress to cirrhosis and liver cancer. Direct-acting antiviral treatment can significantly improve the prognosis of the disease and the efficacy is seemingly not…
- Trial name
- NCT03188276
- Testing
- Ledipasvir-Sofosbuvir, Daclatasvir-Sofosbuvir
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Asthma
A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
This Phase 2 protocol is designed to compare two dose levels of Vapendavir versus placebo. The objectives are to obtain safety and efficacy data in moderate to severe asthmatic patients, aged 18 to 75 years at risk of loss of…
- Trial name
- SPIRITUS (NCT02367313)
- Testing
- Vapendavir
- Where
- 62 sites in United States, Bulgaria and 4 more
- Volunteers
- 455 people
- Sponsor
- Biota Pharmaceuticals, Inc.
Hepatitis C, Chronic
GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
The purpose of this phase 2 study is to determine whether 30 mg or 90 mg of GS-5885 when given with GS-9451, Tegobuvir and Ribavirin (RBV) for 12 or 24 weeks is effective, safe and tolerable in the treatment of Chronic Genotype 1…
- Trial name
- NCT01353248
- Testing
- GS-5885, Tegobuvir, GS-9451
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 141 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C
This study is a two-way, non-interventional long-term dynamic follow-up clinical observational cohort study. In the Second Division of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, chronic hepatitis C…
- Trial name
- NCT04301882
- Testing
- interferon combined with ribavirin (PR) antiviral therapy, direct antiviral drugs (DAAs)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Ditan Hospital
Influenza, Pneumonia
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Current guidelines recommend early initiation of empiric antibiotic therapy to cover typical and atypical bacteria that may cause community-acquired pneumonia (CAP).
- Trial name
- RETOS (NCT01248715)
- Testing
- oseltamivir
- Where
- 5 sites in United States
- Volunteers
- 1,107 people
- Sponsor
- University of Louisville
Classical Kaposi's Sarcoma
Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir
Recent studies have described a reduced incidence or the regression of Kaposi's sarcoma (KS) in HIV-infected patients treated with the highly active anti-retroviral therapy (HAART) that contains at least one inhibitor of the HIV…
- Trial name
- NCT00362310
- Testing
- indinavir
- Where
- 9 sites in Italy
- Volunteers
- 28 people
- Sponsor
- Istituto Superiore di Sanità
PTSD
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement…
- Trial name
- NCT05637879
- Testing
- Glecaprevir/pibrentasvir
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- White River Junction Veterans Affairs Medical Center
HIV Infections
A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV Therapy
To evaluate the safety of zalcitabine (dideoxycytidine; ddC) alone and in combination with zidovudine (AZT) versus AZT alone when administered to asymptomatic patients with a CD4 count = or < 200 cells/mm3 and symptomatic…
- Trial name
- NCT00000651
- Testing
- Zidovudine, Zalcitabine
- Where
- 40 sites in United States
- Volunteers
- 750 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, HIV
Control and Elimination Within Australia of Hepatitis C From People Living With HIV
The purpose of this study is to evaluate the feasibility of rapid scale-up of new hepatitis C (HCV) treatments, known as interferon-free Direct Acting Antiviral (DAA) drugs, and impact on the proportion of people with HCV within…
- Conditions
- Hepatitis C, HIV, HIV-HCV Coinfection
- Trial name
- CEASE (NCT02102451)
- Where
- 18 sites in Australia
- Volunteers
- 492 people
- Sponsor
- Kirby Institute
Cirrhosis, Chronic Hepatitis C
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
Background: Some people who have chronic hepatitis C do not respond to the usual treatment with peginterferon and ribavirin. New chronic hepatitis treatments are being developed that may work better for different people.
- Conditions
- Cirrhosis, Chronic Hepatitis C, Hepatitis C, Hepatitis C, Chronic
- Trial name
- NCT01888900
- Testing
- DUAL, QUAD
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C
Ribavirin Bioavailability After Telaprevir Exposure
Anemia is more frequent in patients receiving telaprevir with pegylated-interferon/ribavirin than in those receiving pegylated-interferon/ribavirin alone.
- Trial name
- NCT02881034
- Testing
- Triple therapy
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Hospices Civils de Lyon
Chronic Hepatitis b
Effort to Narrow the Gap Between in Accordance With Guidelines and Consent to Treat CHB Population in East of China
China has the world's largest burden of hepatitis B virus (HBV) infection and will be a major contributor towards the global elimination of hepatitis B disease by 2030.
- Trial name
- GATE (NCT04980664)
- Testing
- Integrated intervention strategies
- Where
- 4 sites in China
- Volunteers
- 2,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Hepatocellular Carcinoma, Hepatitis B Virus
Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma
Most hepatocellular carcinomas are associated with hepatitis B virus, it is hypothesized that anti-viral treatment may be helpful in treating HBV-related hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma, Hepatitis B Virus, Recurrence
- Trial name
- NCT00768157
- Testing
- antiviral treatment (lamivudine or entecavir), radical resection of HBV-related HCC
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Non-alcoholic Fatty Liver Disease, Renal Function Impairment
Analysis of Renal Impairment Characteristics and High-Risk Factors in Chronic Hepatitis B Patients on Long-Term Oral Nucleos(t)Ide Analogues
This is a single-center retrospective observational study. A total of 300 patients with non-alcoholic fatty liver disease treated in our hospital will be included.
- Trial name
- NCT07730905
- Testing
- Long-term oral nucleos(t)ide analogs antiviral therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Foshan Hospital of Traditional Chinese Medicine
Hepatitis B, Chronic
Patients With Chronic Hepatitis B and Low Viremia Not Receiving Antiviral Therapy
This observational long-term follow-up study will evaluate demographic, clinical, histological, biochemical, and virological parameters of patients with chronic hepatitis B and low viremia who do not require antiviral therapy…
- Trial name
- NCT01090531
- Where
- 6 sites in Germany
- Volunteers
- 1,000 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Chronic Hepatitis B
A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Reverse Transcriptase Inhibitors
This is a multicenter, randomized, controlled Phase IIa study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus.
- Trial name
- NCT05839639
- Testing
- NrtIs, HH-003, HH-003+NrtIs
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Huahui Health